Blog

CHO cells are essential for antibody production. Biointron highlights why they are the backbone of scalable, high-yield recombinant protein systems.

Bispecific antibodies expand therapeutic frontiers. Biointron explores how bsAbs are advancing drug development and reshaping clinical practice.

Pembrolizumab became the first tissue-agnostic therapy. Biointron reviews its approval and transformative impact on oncology treatment strategies.

Ipilimumab pioneered checkpoint inhibition. Biointron explains its approval, mechanism, and importance as the first immune checkpoint inhibitor.

Blinatumomab marked a milestone as the first bispecific in oncology. Biointron reviews its approval and impact on cancer immunotherapy.

Gemtuzumab Ozogamicin was the first approved ADC. Biointron highlights its development and role in shaping targeted cancer therapies.

Oncology drug development has pivotal milestones. Biointron reviews major moments that reshaped antibody therapeutics over the past 25 years.

Bispecific antibodies advance cancer treatment. Biointron explains engineering strategies and therapeutic applications that expand oncology options.

Antibodies to watch in 2025 showcase innovation. Biointron highlights new developments shaping modern antibody therapies and their impact on medicine.

VHH antibodies, or nanobodies, offer promise in biotech. Biointron outlines future directions for their research, applications, and therapeutic potential.

Monoclonal antibodies have shaped medicine. Biointron reviews their evolution, therapeutic applications, and the future of antibody-based therapies.

Bispecific antibodies drive innovation in therapy. Biointron explores their clinical applications, design benefits, and potential to transform treatments.